Neuren Pharmaceuticals
Camberwell South · Founded 2004
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and development in metabolic disorders such as cancers related to the functions of growth hormone. Neuren has three lead candidates; Motiva™ and NNZ-2566 presently in clinical development to treat three different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions. Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).
Company Facts
- Founded: 2004
- Legal name: Neuren Pharmaceuticals Ltd
- Operating status: IPO
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $100K – $500K
- Total funding: $28.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2013)
- Website: neurenpharma.com
- Phone: +61390920480
Social Profiles
Canonical: https://fsome.com/organization/neuren-pharmaceuticals-8260723 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.